No Data
No Data
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
[Brokerage Focus] BOCOM INTL points to new opportunities in the medical Sector driven by AI technology, focusing on innovation related to AI and opportunities for valuation recovery.
Jingu Finance News | BOCOM INTL stated that multiple pharmaceutical companies have integrated DeepSeek, accelerating the implementation of AI + Medical Services. Many companies in the digital medical field, such as Yidu Technology, announced the integration of DeepSeek-R1 model, and Jiangsu Hengrui Pharmaceuticals and INNOVENT BIO also indicated that they will fully carry out DeepSeek application work. Moreover, the National Healthcare Security Administration has reiterated the reform of payment collection. The administration mentioned the achievements of the settlement reform in Jiangxi Province, where the payment collection cycle for medical supply companies has reduced from half a year to 30 days. The bank pointed out that AI large models empower digital medical services companies, showing significant potential in disease diagnosis/detection. At the same time,
Hong Kong Stock Announcement Gold Mining | IGG expects to achieve a net income of approximately 0.58 billion Hong Kong dollars in the year 2024, a significant year-on-year increase of about 700%.
ND PAPER (02689) issued a positive profit alert, expecting mid-term Net income of 0.65 billion to 0.7 billion yuan, a year-on-year increase of 110% to 130%; MEITU (01357) issued a positive profit alert, expecting a year-on-year increase of about 52% to 60% in the fiscal year 2024's Net income attributable to the parent company.
SINO BIOPHARM: "Loxoprofen Sodium Gel Patch" has been approved for market launch.
SINO BIOPHARM (01177) announced that the group's developed "Loxoprofen Sodium Gel Patch" (trademark name: Deshu Ping) has received market approval from the China National Medical Products Administration for the treatment of the following diseases and symptoms: inflammation and pain caused by osteoarthritis, muscle pain, and swelling pain due to injury. Deshu Ping is the only Loxoprofen Sodium Gel Patch on the market that has passed consistency evaluation and been verified by clinical trials. Loxoprofen sodium is a propionic acid non-steroidal anti-inflammatory drug that exerts its anti-inflammatory, antipyretic, and analgesic effects by inhibiting cyclooxygenase and blocking prostaglandin synthesis. Compared to other non-steroidal anti-inflammatory drugs.
SINO BIOPHARM: "Torsemide Patch" has been approved for marketing.
SINO BIOPHARM (01177) announced that the "Tiotropium Patch" (trademark name: Deruituo) has received market approval from the National Medical Products Administration of China, for alleviating symptoms such as difficulty in breathing caused by obstructive airway diseases like bronchial asthma, acute bronchitis, chronic bronchitis, and emphysema. This is the first domestically approved topical patch for obstructive airway diseases. The Tiotropium Patch acts on the β2-receptors of bronchial smooth muscle, by dilating the bronchi and relaxing the tracheal muscles, thus improving lung function, promoting tracheal ciliary movement, and having a cough suppressant effect. Compared to traditional asthma treatment pharmaceuticals.
SINO BIOPHARM (01177.HK): "Loxoprofen Sodium Gel Patch" has been approved for market launch.
On February 7, Gelonghui reported that SINO BIOPHARM (01177.HK) announced that the "Loxoprofen Sodium Gel Patch" (trademark name: Deshuping) developed by the group has obtained marketing approval from the National Medical Products Administration of China. It is indicated for the treatment of the following diseases and symptoms: inflammation and pain associated with osteoarthritis, muscle pain, and swelling pain caused by external injuries. Deshuping is the only Loxoprofen Sodium Gel Patch in China that has passed consistency evaluation and been verified through clinical trials before being marketed. Loxoprofen Sodium is a phenylpropanoic acid non-steroidal anti-inflammatory drug that acts by inhibiting cyclooxygenase and blocking prostaglandin synthesis, thus providing anti-inflammatory, antipyretic, and analgesic effects.